YOUR GUIDE TO

TECENTRIQ® SC

atezolizumab subcutaneous

You have been prescribed **TECENTRIQ® SC** as treatment for your cancer. TECENTRIQ SC can be used on its own or with other medicines. This leaflet will explain more about your treatment and should be used in conjunction with the patient booklet provided.

This resource, developed by Roche Products (New Zealand) Ltd, is intended as an educational support item for patients prescribed TECENTRIQ SC.

FREQUENTLY ASKED QUESTIONS:

TREATMENT WITH TECENTRIQ® SC

How is TECENTRIQ SC given?

TECENTRIQ SC will be injected under your skin (also known as 'subcutaneously'), into your thigh, by a doctor or nurse. This is different to TECENTRIQ IV, which is given by a slow drip into a vein (or 'intravenously').



How long does it take to receive TECENTRIQ SC?

The injection will take about 7 minutes.

How often will I have to receive TECENTRIQ SC?

TECENTRIQ SC is given every 3 weeks.

This schedule may be different from what you are used to if you have previously received TECENTRIQ IV.



FREQUENTLY ASKED QUESTIONS:

TREATMENT WITH TECENTRIQ® SC

What side effects might I have?

As TECENTRIQ SC is given under the skin, you may have injection site reactions. These are usually mild and may be described as:

If you experience, or are worried about injection site reactions, please let your doctor or nurse know.

My specialist has changed my medicine from TECENTRIQ IV to TECENTRIQ SC. Do they work the same way?

TECENTRIQ SC and TECENTRIQ IV both contain the same active substance (atezolizumab) and can be used to treat the same cancers. Any other cancer medicines you may be taking will stay the same when changing to TECENTRIQ SC.

Since TECENTRIQ SC and TECENTRIQ IV contain the same active substance, their side effects are very similar. However, you should always tell your doctor or nurse if you experience any side effects during or after your treatment.

What should I do if I have questions about TECENTRIQ SC?

Please speak with your doctor or nurse if you still have questions after reading this leaflet.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.

This booklet is an educational resource to help you and your whanau learn more about what to expect from treatment with TECENTRIQ® SC. It does not take the place of individual advice from your healthcare professional.

More information about TECENTRIQ can be found in the Consumer Medicine Information available at www.medsafe.govt.nz

Tecentriq® (atezolizumab) 1200mg/20mL and 840mg/14ml and Tecentriq SC (atezolizumab 1875 mg/15 mL solution for subcutaneous injection) are **Prescription Medicines** used for early (has not spread to other parts of the body) and advanced or metastatic (has spread to other parts of the body) non-small cell lung cancer, extensive stage small-cell lung cancer, advanced or metastatic urothelial (bladder and urinary system) cancer, advanced or metastatic triple negative breast cancer and unresectable hepatocellular carcinoma.

Tell your doctor if: you have immune system problems such as Crohn's disease, ulcerative colitis, or lupus; you have inflammation of the lungs (pneumonitis); you have liver problems, such as hepatitis; you have thyroid problems; you are taking other medicines; you have allergies to any other medicines, foods, preservatives or dyes; you are pregnant or breastfeeding or plan to become pregnant or breastfeed. Tell your doctor right away if you become pregnant during treatment with Tecentriq.

Tell your doctor immediately if you notice any of the following signs and symptoms: inflammation of the lungs (new or worsening cough, shortness of breath and chest pain); inflammation of the liver (yellowing of skin or eyes, nausea, vomiting, bleeding or bruising, dark urine, and stomach pain); inflammation of the intestines (diarrhoea, blood in stools, and stomach pain); inflammation of the thyroid, pituitary and adrenal glands (tiredness, weight loss, weight gain, changes in mood or behaviour, visual disturbances, increased sensitivity to cold or heat, slow or rapid heart rate, hair loss, constipation, headache, and dizziness); type 1 diabetes mellitus (feeling more hungry or thirsty than usual, need to urinate more often, weight loss, and feeling tired); inflammation of the brain or spinal cord (neck stiffness, headache, fever, chills, vomiting, eye sensitivity to light, confusion and sleepiness); inflammation of the nerves (muscle weakness, numbness or tingling in hands and feet); inflammation of the pancreas (abdominal pain, nausea and vomiting); inflammation of the heart muscle (shortness of breath, feeling tired, irregular heart beat or chest pain); inflammation of the sac surrounding the heart (chest pain, difficulty and/or painful breathing, pounding/racing heart beat, fainting and/or light-headedness, swelling of legs or abdomen, pale and/or clammy skin); inflammation of the kidneys (dark and/or frothy urine, high blood pressure, swelling to face, feet, legs and hands; inflammation of muscles (muscle pain or stiffness or skin rash); infusion reactions (fever, chills, shortness of breath and flushing - intravenous formulation only), local reaction at the injection site (subcutaneous formulation only), excessive activation of the immune system (fever, swollen lymph nodes, skin rash, yellowing of skin and eyes, coughing, difficulty breathing, vomiting, diarrhea headache, changes in vision, weakness), paralysis of the facial muscles, inflammation of the spinal cord (muscle weakness in the legs and arms, numbness, problems with mobility, the bladder and bowel) or any inflammation of the skin.

Possible common side effects may also include: loss of appetite; diarrhoea; shortness of breath; itching of the skin; dry skin; rash; nausea; fever; chills; vomiting; difficulty swallowing; flu-like symptoms; nasal congestion; stomach, back, muscle, bone, joint or throat pain; cough; sore throat; tiredness; common cold; headaches; being short of breath when exercising; urinary tract infection; lung infection; dizziness, light-headedness, looking pale, fainting; bleeding or bruising; mouth ulcers and/or cold sores; constipation; numbness or weakness of the arms and legs; high blood pressure; hair loss; a change in the way things taste.

Tecentriq has risks and benefits. Ask your doctor if Tecentriq is right for you. Use strictly as directed. If symptoms continue or you have side effects, see your healthcare professional. For further information on Tecentriq, please talk to your health professional or visit www.medsafe.govt.nz for Tecentriq Consumer Medicine Information.

Tecentriq (intravenous formulation) is PHARMAC funded for patients with locally advanced or metastatic NSCLC that have previously received chemotherapy. A prescription charge and normal oncologist fees may apply.

Tecentriq (intravenous formulation) is not PHARMAC funded for urothelial cancer, breast cancer, hepatocellular carcinoma and other lung cancer indications. Tecentriq SC is not PHARMAC funded for any indication. You will need to pay the full cost of the medicine. A prescription charge and normal oncologist fees may apply.

Roche Products (New Zealand) Limited, Auckland.
Phone: 0800 276 243. www.roche.co.nz.

M-NZ-00001086/MR10851/AUG2024 ROC00775

TECENTRIQ® SC
atezolizumab subcutaneous